Table 1_Systemic treatment strategies for BRAF wild-type metastatic unresectable melanoma: a network meta-analysis.docx

Notably, nivolumab + relatlimab ranked first in prolonging OS (SUCRA = 93.94%). In the PFS analysis, this regimen had the highest SUCRA value only within the connected network consisting of dacarbazine, nivolumab, and the combination of nivolumab and relatlimab (SUCRA = 98.86%), although no comparisons or standardized rankings were performed between different PFS networks.</p>Conclusions<p>The results of OS primary analysis for nivolumab plus relatlimab, as well as its ranking within the corresponding PFS network, are exploratory in nature.

They are intended solely to generate research hypotheses and should not be interpreted as evidence of superiority over other treatments or as a basis for changing the current standard of care. Direct head-to-head RCTs are still needed to further clarify the comparative efficacy of the relevant regimens.</p>